Paramus, New Jersey Clinical Trials

A listing of Paramus, New Jersey clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 81 clinical trials
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine Cyclophosphamide and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or bendamustine + rituximab (FCR/BR) in FIT participants (FIT is defined by a cumulative illness rating scale [CIRS]/score of 6 and a normal creatinine clearance of 70 mL/min) …

leukemia
platelet count
myelodysplastic syndrome
obinutuzumab
chronic lymphocytic leukemia
Regional Cancer Care Associates
 (4.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +50 other locations
Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

Primary Objective: To determine whether SAR439859 per os improves progression free survival (PFS) when compared with a endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer. Secondary Objectives: To compare the overall survival in the 2 treatment arms To assess the objective …

HER2
stage iv breast cancer
breast cancer
estrogen receptor
adjuvant
Investigational Site Number 8400025
 (4.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +130 other locations
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis (FREVIVA)  

The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to approximately 51 months administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at …

Holy Name Medical Center Site Number : 8400101
 (4.8 away)
  • 0 views
  • 04 Mar, 2025
  • +58 other locations
Trial With the Treatment of Sertraline in Youth With Generalized Separation and/or Social Anxiety Disorders.

A Multicenter, acute, randomized, double-blind, placebo-controlled, flexible-dose trial with the treatment of sertraline.

psychosis
estrogen
progestin
adjustment disorder
sertraline
University of Columbia, New York State Psychiatric Institute
 (9.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) Before and During Treatment With Ocrelizumab

This is an open-label, multicenter study that includes a main study for all participants enrolled and an optional cerebrospinal fluid (CSF) sub-study. Self-identified African American (AA) and Hispanic or Latin American (HA) participants with a diagnosis of relapsing multiple sclerosis (RMS) will be enrolled. The treating neurologist must make an …

Hackensack University Medical Center
 (4.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +30 other locations
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

This is a global, Phase 1/2, multicenter, open-label study. The clinical study will include of Phase 1: Dose Escalation (non-randomized, dose finding study) and Phase 2: Dose Expansion (randomized efficacy exploration). For Phase 1, the purpose of this study is to assess the maximum tolerated dose (MTD), recommend phase 2 …

selinexor
measurable disease
genetic testing
recurrent disease
platelet count
Hackensack Meridian Health, 92 Second Street
 (4.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy

The purpose of this additional part of the study is to test whether the study drug, nivolumab, is a safe treatment that will prevent participants' primary central nervous system lymphoma (PCNSL) from growing again (recurrence). Participants will be people with PCNSL who continue to have cell free tumor DNA (cfDNA) …

blood transfusion
international normalized ratio
ct scan
gilbert's syndrome
ffpe
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
 (7.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +6 other locations
Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients

A multicenter, randomized, adaptive allocation clinical trial to determine if increasing durations of induced hypothermia are associated with an increasing rate of good neurological outcomes and to identify the optimal duration of induced hypothermia for neuroprotection in comatose survivors of cardiac arrest.

hypothermia
coma
life support
cardiac arrest
induced hypothermia
NYP Columbia University Medical Center
 (9.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +12 other locations
Manhattan Vision Screening and Follow-Up Study

The investigators are conducting a 5-year prospective, cluster-randomized controlled trial, funded by the Centers for Disease Control (CDC), which provides vision screenings to underserved, vulnerable New York City residents living in affordable housing buildings in Harlem and Washington Heights.

vision screening
Columbia University
 (9.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.

cancer therapy
immunomodulator
endometrial carcinoma
measurable disease
recurrent disease
Research Site
 (0.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +94 other locations